Table 3.
Author | Total cases | TKIs | Response rate (%) | PFS (months) |
---|---|---|---|---|
Shukuya et al16 | 16 | G | 38.0 | 3.1 |
Cho et al10 | 8 | G, E | 37.5 | 4.1 |
Fang et al12 | 15 | G, E | 26.7 | 3.9 |
Xu et al9 | 26 | G, E, I | 30.8 | 3.98 |
Abbreviations: E, erlotinib; EGFR, epidermal growth factor receptor; G, gefitinib; I, cotinibwen; PFS, progression-free survival; TKIs, tyrosine kinase inhibitors.